A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
复制标题
DOI:
10.4161/onci.26852
复制
发表时间:
2013-12-01
期刊:
影响因子:
7.2
通讯作者:
Bigner DD
中科院分区:
文献类型:
--
作者:
Chandramohan V;Bigner DD
Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.
登录
查看更多内容
影响因子:
158.5
作者:
Stupp, R;Mason, WP;Ryan, G
通讯作者:
Ryan, G
影响因子:
3.1
作者:
Zalutsky MR;Boskovitz A;Kuan CT;Pegram CN;Ayriss J;Wikstrand CJ;Buckley AF;Lipp ES;Herndon JE 2nd;McLendon RE;Bigner DD
通讯作者:
Bigner DD
DOI:
10.2217/fon.13.47
发表时间:
2013-07
期刊:
Future oncology (London, England)
影响因子:
--
作者:
Chandramohan V;Mitchell DA;Johnson LA;Sampson JH;Bigner DD
通讯作者:
Bigner DD
影响因子:
5.2
作者:
Lv, Shasha;Teugels, Erik;Neyns, Bart
通讯作者:
Neyns, Bart
影响因子:
--
作者:
Chandramohan V;Sampson JH;Pastan I;Bigner DD
通讯作者:
Bigner DD